IRMD IRADIMED CORP
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1325618 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY11.0%
TTM net income YoY13.2%
TTM EPS YoY13.3%
Revenue 3-yr CAGR12.4%
Net income 3-yr CAGR13.7%
Margins
Gross margin75.5%
Operating margin32.3%
Net margin26.8%
FCF margin29.3%
EBITDA margin33.9%
Returns
ROE23.4%
ROA20.3%
ROIC (approx.)52.3%
Asset turnover0.76x
Leverage & solvency
Liabilities / assets12.1%
Debt / equity0.00x
Current ratio8.99x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.13x
Accruals ratio-2.7%
Payout ratio67.7%
Capex / revenue1.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $24.20M | $20.47M | $21.98M | $22.69M | $21.20M | $20.41M | $19.51M | $19.39M |
| Cost of revenue | $5.75M | $5.31M | $5.17M | $5.66M | $4.71M | $4.45M | $4.67M | $4.63M |
| Gross profit | $18.46M | $15.16M | $16.81M | $17.03M | $16.49M | $15.96M | $14.84M | $14.76M |
| R&D expense | $875,000 | $657,000 | $956,000 | $799,031 | $674,000 | $877,000 | $624,000 | $569,993 |
| SG&A expense | $4.53M | $3.87M | $4.57M | $4.54M | $4.36M | $4.28M | $4.61M | $3.87M |
| Operating income | $8.14M | $6.39M | $7.24M | $7.09M | $6.83M | $6.79M | $5.43M | $5.80M |
| Pretax income | $8.67M | $6.89M | $7.77M | $7.79M | $7.30M | $7.33M | $5.95M | $6.34M |
| Income tax | $2.16M | $1.67M | $1.95M | $1.35M | $1.72M | $1.55M | $1.26M | $1.20M |
| Net income | $6.51M | $5.22M | $5.82M | $6.44M | $5.58M | $5.77M | $4.69M | $5.15M |
| EBITDA | $8.44M | $6.69M | $7.69M | $7.47M | $7.09M | $6.92M | $5.63M | $6.00M |
| EPS (basic) | 0.51 | 0.41 | 0.46 | — | 0.44 | 0.45 | 0.37 | — |
| EPS (diluted) | 0.51 | 0.41 | 0.45 | — | 0.43 | 0.45 | 0.37 | — |
| Weighted avg. shares (diluted) | 12.88M | 12.87M | 12.87M | — | 12.86M | 12.84M | 12.83M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $63.29M | $59.08M | $56.37M | $51.16M | $56.53M | $53.00M | $50.33M | $52.23M |
| Receivables | $13.67M | $13.19M | $13.41M | $13.67M | $13.86M | $10.92M | $12.71M | $10.56M |
| Inventory | $13.49M | $12.26M | $11.88M | $11.62M | $11.73M | $11.20M | $10.56M | $10.40M |
| Current assets | $92.80M | $86.72M | $86.42M | $81.20M | $84.92M | $77.37M | $75.14M | $75.24M |
| PP&E, net | $24.08M | $24.21M | $24.23M | $23.86M | $23.79M | $22.94M | $20.38M | $16.81M |
| Intangibles | $3.41M | $3.44M | $3.29M | $3.38M | $3.37M | $3.37M | $3.26M | $3.10M |
| Total assets | $121.07M | $114.97M | $114.39M | $108.78M | $114.72M | $106.45M | $101.73M | $98.33M |
| Current liabilities | $10.32M | $9.16M | $12.12M | $10.18M | $12.80M | $8.81M | $8.47M | $8.51M |
| Total liabilities | $14.62M | $13.23M | $15.88M | $14.16M | $16.37M | $12.15M | $11.68M | $11.51M |
| Shareholders' equity | $106.45M | $101.75M | $98.51M | $94.62M | $98.35M | $94.30M | $90.06M | $86.82M |
| Shares outstanding | 12.79M | 12.79M | 12.78M | 12.78M | 12.72M | 12.72M | 12.72M | 12.71M |
| Cash flow statement | ||||||||
| Operating cash flow | $7.00M | $5.94M | $8.29M | $5.92M | $6.99M | $7.75M | $4.29M | $5.99M |
| Capital expenditure | $130,000 | $185,000 | $403,000 | $294,174 | $1.14M | $2.64M | $3.70M | $2.79M |
| Free cash flow | $6.87M | $5.75M | $7.89M | $5.63M | $5.85M | $5.11M | $595,000 | $3.20M |
| Investing cash flow | -$212,000 | -$443,000 | -$469,000 | -$416,407 | -$1.26M | -$2.82M | -$3.92M | -$3.06M |
| Financing cash flow | -$2.58M | -$2.79M | -$2.61M | -$10.87M | -$2.19M | -$2.26M | -$2.28M | -$2.42M |
| Depreciation & amortization | $305,000 | $303,000 | $455,000 | $381,000 | $256,000 | $136,000 | $194,000 | $195,210 |
| Stock-based compensation | $777,000 | $807,000 | $684,000 | $696,236 | $666,000 | $731,000 | $826,000 | $656,835 |
| Dividends paid | $2.56M | $2.56M | $2.56M | $8.55M | $2.16M | $2.16M | $2.16M | $1.90M |
Free plan shows the latest 8 periods; Pro shows all 54 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.